European Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA® (edoxaban) - Seite 2

trial settings. Additionally, rates of all other cardiovascular
events were also low in these patients," said Professor Raffaele De
Caterina, Professor of Cardiology, Institute of Cardiology at the
University of Pisa, Italy. "Atrial fibrillation is the most common
form of arrhythmia in patients over the age of 65, and its prevalence
increases with age. As such, it is critical that we understand the
safety and efficacy profile of edoxaban in elderly populations."

The wider Global ETNA-AF programme, which at present is the
largest and most comprehensive repository of routine clinical
practice data on the use, effectiveness, and safety of a single NOAC
in patients with atrial fibrillation (AF), collected data from 24,962
patients in 2,242 sites in Japan, Korea/Taiwan and Europe.

"These positive results provide great insight into the safety and
efficacy profile of edoxaban in NVAF patients, particularly in those
who are elderly and/or those with comorbidities, who are considered
at higher risk of cardiovascular events," said Wolfgang Zierhut, MD,
Executive Director Medical Affairs and Head Thrombosis and
Cardiovascular at Daiichi Sankyo Europe. "Findings from ETNA-AF
demonstrate that Phase III efficacy and safety results from the
ENGAGE AF-TIMI-48 clinical study are being confirmed in regular
routine clinical care across the region."

About ETNA-AF

ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in
patients with nonvalvular Atrial Fibrillation) is a global programme
that combines data from distinct non-interventional studies in
Europe, East Asia, and Japan in a single database. A total of more
than 28,000 patients will be included in the ETNA-AF registries and
followed for two years (patients in Europe will be followed for four
years). The primary objective of ETNA-AF is to collect information on
the use of edoxaban in routine clinical practice, including the
safety and efficacy profile in non-preselected patients with
NVAF.3,4,5,6,7

About Atrial Fibrillation

AF is a condition where the heart beats irregularly and rapidly.
When this happens, blood can pool and thicken in the chambers of the
heart causing an increased risk of blood clots. These blood clots can
break off and travel through the blood stream to the brain (or
sometimes to another part of the body), where they have the potential
to cause a stroke.8

AF is the most common type of heart rhythm disorder and is
associated with substantial morbidity and mortality.9 More than six
million Europeans are diagnosed with AF, and this figure is expected